How to Use ARA-290
Complete guide to ARA-290 dosing, administration, timing, and protocol recommendations.
Quick Overview
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Dosing Guidelines
Common Dose
4 mg daily
Frequency
Once daily
Dose Range
4-8 mg daily
Note: Cibinetide. Clinical trial doses. Used for neuropathy and sarcoidosis. Non-erythropoietic EPO derivative.
Administration Method
Subcutaneous injection
Best Time to Take
Consistent daily timing
Clinical trials used once-daily dosing at consistent times
Protocol Duration
28-day courses in trials
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated in trials
- •Injection site reactions
- •No erythropoietic effects (no blood thickening)
- •Not FDA approved
Frequently Asked Questions
What is the recommended dose for ARA-290?
4 mg daily
How do you administer ARA-290?
Subcutaneous injection
When is the best time to take ARA-290?
Consistent daily timing
How long should you use ARA-290?
28-day courses in trials
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.